Efficacy and safety of fixed-dose combination calcipotriol/betamethasone dipropionate foam for the treatment of psoriasis
Carregando...
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2021
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
Citação
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, v.35, suppl.1, Special Issue, p.10-19, 2021
Resumo
The fixed-dose combination calcipotriol (Cal; 50 mu g/g) plus betamethasone dipropionate (BD; 0.5 mg/g) ointment and gel formulations have well-established efficacy profiles in the treatment of psoriasis vulgaris (chronic plaque psoriasis); this combination has been shown to produce favourable outcomes versus either monotherapy. To improve upon the efficacy and cosmetic acceptability of these treatments Cal/BD foam was developed, demonstrating superior efficacy in Phase II/III studies compared with either of its monocomponents, Cal/BD ointment, Cal/BD gel and various other therapies for the treatment of psoriasis. Multiple outcome measures were evaluated in the clinical studies, including physician's global assessment of disease severity and modified psoriasis area and severity index. Of note, 38-55% of patients across studies achieved a physician's global assessment of 'clear' or 'almost clear' after 4 weeks of Cal/BD treatment. This superior efficacy was not associated with an increased frequency or severity of adverse events, and there was no evidence for dysregulation of the hypothalamic-pituitary-adrenal axis or calcium homeostasis. Overall, Cal/BD foam was efficacious, with a good tolerability profile consistent with established Cal/BD formulations.
Palavras-chave
Referências
- Bagel J, 2018, J DRUGS DERMATOL, V17, P845
- Bewley A, 2014, J EUR ACAD DERMATOL, V28, P763, DOI 10.1111/jdv.12174
- Bewley AP, 2019, J EUR ACAD DERMATOL, V33, P1107, DOI 10.1111/jdv.15369
- Zurita C, 2017, J DERMATOL TREAT, V28, P401, DOI 10.1080/09546634.2016.1273469
- Chiricozzi A, 2017, DERMATOL THER, V30, DOI 10.1111/dth.12453
- Gold LS, 2016, DERMATOLOGY THER, V6, P667, DOI 10.1007/s13555-016-0
- Inzinger M, 2013, J EUR ACAD DERMATOL, V27, P861, DOI 10.1111/j.1468-3083.2012.04596.x
- Koo J, 2016, J DERMATOL TREAT, V27, P120, DOI 10.3109/09546634.2015.1083935
- Lebwohl Mark, 2016, J Clin Aesthet Dermatol, V9, P34
- Leonardi C, 2015, J DRUGS DERMATOL, V14, P1468
- Paul C, 2017, J EUR ACAD DERMATOL, V31, P119, DOI 10.1111/jdv.13859
- Paul C, 2017, AM J CLIN DERMATOL, V18, P405, DOI 10.1007/s40257-017-0258-0
- Queille-Roussel C, 2017, CLIN DRUG INVEST, V37, P355, DOI 10.1007/s40261-016-0489-5
- Seyger M, 2020, J EUR ACAD DERMATOL, V34, P2026, DOI 10.1111/jdv.16233
- Strober B, 2017, J DRUGS DERMATOL, V16, P801
- Tada Y, 2021, J EUR ACAD DERMATOL, V35, P5, DOI 10.1111/jdv.17027
- Wigger-Alberti W, 2017, SKIN PHARMACOL PHYS, V30, P102, DOI 10.1159/000458415